TERNS PHARMACEUTICALS INC. - COMMON STOCK

Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer

10 Apr 2024 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates

14 Mar 2024 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia

11 Mar 2024 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

07 Mar 2024 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences

27 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grants to New Chief Executive Officer Under Nasdaq Listing Rule 5635(C)(4)

07 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Appoints Amy Burroughs as Chief Executive Officer

07 Feb 2024 07:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

02 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Highlight 2024 Priorities and Clinical Milestones at the 42nd Annual J.P. Morgan Healthcare Conference

04 Jan 2024 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

03 Jan 2024 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit

29 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Mourns the Loss of Senthil Sundaram, Former Chief Executive Officer

27 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Updates

14 Nov 2023 07:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Presents Late-Breaking Data from Phase 2a DUET Trial of THR-β Agonist TERN-501 in NASH at AASLD The Liver Meeting® 2023

13 Nov 2023 07:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences

09 Nov 2023 07:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

03 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of TERN-601 Oral GLP-1 Receptor Agonist for Treatment of Obesity

02 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Participate in Upcoming Investor Conferences

19 Oct 2023 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Announces Global Phase 1 Clinical Trial Design of TERN-701 for the Treatment of Chronic Myeloid Leukemia

16 Oct 2023 07:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

03 Oct 2023 15:05:00 By Nasdaq GlobeNewswire